Lipid Nanoparticle Composition for Stable mRNA Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
mRNA vaccines face challenges due to the instability of RNA and inefficient in vivo delivery, which hampers their development and deployment.
Innovation Solution
A pharmaceutical composition comprising lipid nanoparticles (LNPs) with specific lipid ratios encapsulating mRNA, including cationic, PEGylated, cholesterol-based, and helper lipids, enhances mRNA stability and cellular uptake, facilitating efficient delivery and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional subunit vaccines using recombinant proteins are used, then antigenic proteins can be produced, but complex purification processes and high manufacturing costs are required
Solution Approach 1:
The patent extracts the complex purification steps from the manufacturing process by using mRNA vaccines that express antigens directly in host cells, eliminating the need for complex protein purification while maintaining antigen quality and functionality
Solution Approach 2:
The mRNA vaccine approach allows the host's cellular machinery to self-produce the antigen through translation of the mRNA, eliminating the need for external complex purification processes and reducing manufacturing complexity
2Reliability
If mRNA vaccines are used to enable de novo expression of antigens, then proper post-translational modification is achieved, but RNA instability and rapid degradation occur
Solution Approach 1:
The patent introduces lipid nanoparticles as intermediary carriers that protect the unstable mRNA from degradation while delivering it to host cells, enabling the mRNA to maintain its integrity and function without direct exposure to degrading enzymes
Solution Approach 2:
The LNP formulation provides beforehand protection to the mRNA against degradation by encapsulating it in a protective lipid shell before administration, cushioning the fragile mRNA from nucleases and environmental factors
3Object-affected harmful factors
If mRNA vaccines are administered, then transient antigen expression without genome integration is achieved, but inefficient in vivo delivery of mRNA occurs
Solution Approach 1:
The lipid nanoparticle serves as an intermediary delivery vehicle that facilitates efficient mRNA uptake by host cells through endocytosis, overcoming the inherent inefficiency of direct mRNA administration while maintaining the safety profile of transient expression
Solution Approach 2:
The patent replaces direct mechanical injection of mRNA with a biochemical delivery mechanism using LNPs that utilize cellular endocytic pathways for internalization, improving delivery efficiency without compromising the transient and safe expression characteristic
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNP formulation achieves enhanced mRNA stability, improved cellular uptake, and induces robust humoral and cellular immunity, demonstrating superior potency and immunogenicity compared to existing formulations.
Implementation Method 1
nucleic acid molecules (e.g., mRNA molecules) encapsulated in lipid nanoparticles (LNPs)
Implementation Method 2
each LNP comprises a cationic lipid at a molar ratio between 35% and 45%
Implementation Method 3
a polyethylene glycol (PEG) conjugated (PEGylated) lipid at a molar ratio between 0.25% and 2.75%
Implementation Method 4
improved cellular uptake, and induces robust humoral and cellular immunity
Data Source
AI summary
Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.